Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 May 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Expanded access
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Nov 2016 Status changed from recruiting to completed.
    • 05 Nov 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Apr 2015 according to CliniclTrials.gov record.
    • 20 Aug 2014 Planned End Date changed from 1 Jun 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top